GlassScriptPhysician profile
Jon R Hillyer
NPI 1255398178
$20,190.86
in general payments reported to CMS, 2019-2025
47 companies · $14K in 2025
The $14K reported for 2025 was more than what 96% of Pain Medicine (Anesthesiology) providers received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,179 · 2020: $874 · 2021: $1,246 · 2022: $1,101 · 2023: $798 · 2024: $700 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $2,504 · Travel and Lodging: $842.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,445.00 |
| Food and Beverage | $2,504.14 |
| Travel and Lodging | $842.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $13,709.51 | 2025 | |
| Nevro Corp. | $1,016.76 | 2019-2024 | Senza |
| Boston Scientific Corporation | $723.82 | 2019-2025 | General - Pain Management, Intracept, Wavewriter Alpha Prime 16 |
| Abbvie INC. | $700.77 | 2021-2025 | |
| Medtronic, INC. | $443.82 | 2021-2024 | Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $420.11 | 2019-2023 | Belbuca, Xtampza |
| Saluda Medical Americas, INC. | $355.73 | 2024-2025 | Evoke |
| Pfizer INC. | $324.84 | 2019-2021 | |
| Nalu Medical, INC. | $226.80 | 2021-2023 | Nalu Neurostimulation System |
| Amgen INC. | $188.73 | 2020-2022 | |
| Lilly USA, LLC | $181.15 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.40 | 2020-2023 | Relistor |
| Biohaven Pharmaceuticals, INC. | $123.41 | 2021 | |
| Abbott Laboratories | $113.82 | 2024-2025 | Eterna |
| Tersera Therapeutics LLC | $109.17 | 2019-2025 | Prialt |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Hillyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.